IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation.
IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024.
As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating model is in full effect in the new year. Arora has spent the past 21 years at Kellogg, beginning in India in 2002, where he held roles in marketing and category management. After relocating to the United States in 2005, he assumed roles of increasing responsibility in marketing, brand management and general management for the Cereals, Snacking and Salty Snack categories across the United States. From 2012-2015, he led marketing and innovation for the Asia, Middle East and Africa markets based out of Singapore. He most recently served as President, U.S. Categories for Kellogg North America, where he was responsible for leading the food giant’s U.S. portfolio across six categories.
Arora is a business leader with an excellent track record across multiple geographies, delivering significant portfolio and organizational transformation in support of driving Kellogg’s growth in multiple categories. An award-winning marketer, the depth and breadth of his experience spans brand and category management, product marketing, product innovation and general management.
“Yuvraj will be an outstanding addition to the leadership team,” said Frank Clyburn, CEO, IFF. “His expertise in commercializing innovation and track record of delivering strong P&L performance across food and beverage categories make him a great fit to lead Nourish. Yuvraj’s CPG and consumer insight experience will be of tremendous value as we continue to innovate and create with our customers to enable growth. His deep experience in driving transformation and execution will be instrumental in facilitating IFF’s previously announced transition to a category-backed operating model.”
Arora holds a Bachelor of Technology in Engineering from National Institute of Technology, Calicut and an MBA in Marketing from the University of Delhi, India. He will be based in IFF’s New York headquarters.
IFF also introduced a new divisional leadership structure in alignment with the company’s transformation strategy and new operating model:
Christophe Fauchon de Villeplee, currently President, Scent, will leave IFF after a period of transition. His career at IFF spans more than 24 years, with a total of 30 years in the industry. Since joining IFF in 1999, he held positions of increasing responsibility, including sales, group country management, regional general management of fragrances, North America, and global leadership of Fine Fragrances and Consumer Fragrances.
“We thank Christophe for his service to IFF and wish him the best for his future endeavors,” said Clyburn.
Simon Herriott, currently President, Health & Biosciences, will assume additional responsibilities in leading the Scent division. Herriott will lead IFF’s Home and Personal Care categories when the new operating model is in effect. Since 2019, Herriott has served as platform leader, Health & Biosciences. In a 16-year career with DuPont, Herriott held various leadership positions including in Industrial Biosciences Sustainable Solutions and Chemical Solutions businesses. During his career, he also held multiple roles at ICI, Zeneca and Avecia Inc. in Europe, Asia and North America.
Angela Strzelecki, currently President, Pharma Solutions, will lead IFF’s Health categories when the new operating model is in effect. Over a nearly 30-year career with DuPont, Strzelecki has held a variety of general management, operational and leadership positions across the company, including in Nutrition and Health, Corporate M&A, Titanium Technologies, Building Innovations, Corporate Strategy and Performance Coatings.
IFF will continue to operate in its current business structure for the remainder of 2023, while planning the transition to the new operating model in January 2024.
“Our evolution to a category-aligned operating model is a pivotal moment for IFF,” said Frank Clyburn, IFF CEO. “These proven leaders and the changes we are making will better enable us to bring the full value of the IFF portfolio to our customers, while deepening our commitment to customers and operational excellence. I am confident that our team and enhanced operating framework will benefit our customers, investors, colleagues and the global community of consumers, and position us to execute on IFF’s ambitious growth plans.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.
© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005808/en/
Contact information
Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom